Pinpoint Therapeutics was co-founded by researchers Ravi K. Amaravadi, M.D., and Jeffrey D. Winkler, Ph.D., from Penn’s Abramson Cancer Center and the Department of Chemistry, to develop new autophagy inhibitors as cancer treatments. Autophagy is a well-established mechanism of cancer cell survival and drug resistance, and Pinpoint is developing first-in-class autophagy inhibitors into clinical drugs for testing in a range of treatment-refractory cancer indications. Pinpoint recently raised $1 million in seed financing led by Kairos Ventures. PCI is currently in the final stages of negotiating an exclusive license with the company.
